Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | DRD3 | P35462 | 9/20 | 0.54 |
| ▸ | HTR2A | P28223 | 9/20 | 0.54 |
| ▸ | HTR1A | P08908 | 8/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.54 |
| ▸ | DRD1 | P21728 | 4/20 | 0.54 |
| ▸ | DRD5 | P21918 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 6/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968583 | 0.83 | TP53 (0.55) | DRD2DRD3HTR2AHTR1ASIGMAR1 | |
| SCHEMBL6846732 | 0.82 | MAPT (0.54) | DRD2DRD3HTR2AHTR1ASIGMAR1 | |
| SCHEMBL11713319 | 0.82 | POLB (0.48) | — | |
| SCHEMBL30115042 | 0.81 | ITGB2 (0.58) | SIGMAR1MAPTLMNASMN1; SMN2 | |
| SCHEMBL2489051 | 0.79 | HRH3 (0.70) | — | |
| SCHEMBL7288986 | 0.75 | DRD4 (0.47) | DRD2DRD3SIGMAR1MAPTTP53 | |
| SCHEMBL7290150 | 0.74 | CACNA1G (0.55) | DRD2DRD3HTR2AHTR1ASIGMAR1 | |
| SCHEMBL11447942 | 0.73 | HTR7 (0.60) | DRD2HTR2AHTR1AMAPTTP53 | |
| SCHEMBL2491246 | 0.72 | HRH3 (0.70) | — | |
| SCHEMBL8011318 | 0.72 | DRD2 (0.69) | DRD2DRD3HTR2AHTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5889010-A | PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | PFIZER INC. (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD2 3/4885DRD3 6/4885HTR2A 90/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD2 3/4885DRD3 6/4885HTR2A 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.